Summary

Plantar Fasciitis Treatment Market – Scope of Report
TMR’s report on the global plantar fasciitis treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global plantar fasciitis treatment market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global plantar fasciitis treatment market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the plantar fasciitis treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global plantar fasciitis treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global plantar fasciitis treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global plantar fasciitis treatment market.

The report delves into the competitive landscape of the global plantar fasciitis treatment market. Key players operating in the global plantar fasciitis treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global plantar fasciitis treatment market profiled in this report.

Key Questions Answered in Global plantar fasciitis treatment Market Report
• What is the sales/revenue generated by plantar fasciitis treatment across all regions during the forecast period?
• What are the opportunities in the global plantar fasciitis treatment market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Plantar Fasciitis Treatment Market – Research Objectives and Research Approach
The comprehensive report on the global plantar fasciitis treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global plantar fasciitis treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global plantar fasciitis treatment market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Plantar Fasciitis Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Plantar Fasciitis Treatment Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Plantar Fasciitis Treatment Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2017–2031
6.3.1. Medication Therapy
6.3.1.1. Oral
6.3.1.2. Parenteral
6.3.2. Shockwave Therapy
6.3.2.1. Extracorporeal Shock Wave Therapy (ESWT)
6.3.2.2. Intracorporeal Pneumatic Shockwave Therapy (IPST)
6.3.3. Surgery
6.3.4. Orthotics
6.3.5. Others
6.4. Market Attractiveness Analysis, by Type
7. Global Plantar Fasciitis Treatment Market Analysis and Forecast, by End-user
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by End-user, 2017–2031
7.3.1. Hospitals
7.3.2. Clinics
7.3.3. Others
7.4. Market Attractiveness Analysis, by End-user
8. Global Plantar Fasciitis Treatment Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017–2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Region
9. North America Plantar Fasciitis Treatment Market Analysis and Forecast
9.1. Introduction
9.2. Key Findings
9.3. Market Value Forecast, by Type, 2017–2031
9.3.1. Medication Therapy
9.3.1.1. Oral
9.3.1.2. Parenteral
9.3.2. Shockwave Therapy
9.3.2.1. Extracorporeal Shock Wave Therapy (ESWT)
9.3.2.2. Intracorporeal Pneumatic Shockwave Therapy (IPST)
9.3.3. Surgery
9.3.4. Orthotics
9.3.5. Others
9.4. Market Value Forecast, by End-user, 2017–2031
9.4.1. Hospitals
9.4.2. Clinics
9.4.3. Others
9.5. Market Value Forecast, by Country, 2017–2031
9.5.1. U.S.
9.5.2. Canada
9.6. Market Attractiveness Analysis
9.6.1. By Type
9.6.2. By End-user
9.6.3. By Country
10. Europe Plantar Fasciitis Treatment Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Type, 2017–2031
10.3.1. Medication Therapy
10.3.1.1. Oral
10.3.1.2. Parenteral
10.3.2. Shockwave Therapy
10.3.2.1. Extracorporeal Shock Wave Therapy (ESWT)
10.3.2.2. Intracorporeal Pneumatic Shockwave Therapy (IPST)
10.3.3. Surgery
10.3.4. Orthotics
10.3.5. Others
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Clinics
10.4.3. Others
10.5. Market Value Forecast, by Country/Sub-region, 2017–2031
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Rest of Europe
10.6. Market Attractiveness Analysis
10.6.1. By Type
10.6.2. By End-user
10.6.3. By Country/Sub-region
11. Asia Pacific Plantar Fasciitis Treatment Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Type, 2017–2031
11.3.1. Medication Therapy
11.3.1.1. Oral
11.3.1.2. Parenteral
11.3.2. Shockwave Therapy
11.3.2.1. Extracorporeal Shock Wave Therapy (ESWT)
11.3.2.2. Intracorporeal Pneumatic Shockwave Therapy (IPST)
11.3.3. Surgery
11.3.4. Orthotics
11.3.5. Others
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Clinics
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. China
11.5.2. Japan
11.5.3. India
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Market Attractiveness Analysis
11.6.1. By Type
11.6.2. By End-user
11.6.3. By Country/Sub-region
12. Latin America Plantar Fasciitis Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Type, 2017–2031
12.3.1. Medication Therapy
12.3.1.1. Oral
12.3.1.2. Parenteral
12.3.2. Shockwave Therapy
12.3.2.1. Extracorporeal Shock Wave Therapy (ESWT)
12.3.2.2. Intracorporeal Pneumatic Shockwave Therapy (IPST)
12.3.3. Surgery
12.3.4. Orthotics
12.3.5. Others
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals
12.4.2. Clinics
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Market Attractiveness Analysis
12.6.1. By Type
12.6.2. By End-user
12.6.3. By Country/Sub-region
13. Middle East & Africa Plantar Fasciitis Treatment Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Type, 2017–2031
13.3.1. Medication Therapy
13.3.1.1. Oral
13.3.1.2. Parenteral
13.3.2. Shockwave Therapy
13.3.2.1. Extracorporeal Shock Wave Therapy (ESWT)
13.3.2.2. Intracorporeal Pneumatic Shockwave Therapy (IPST)
13.3.3. Surgery
13.3.4. Orthotics
13.3.5. Others
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals
13.4.2. Clinics
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Market Attractiveness Analysis
13.6.1. By Type
13.6.2. By End-user
13.6.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. Hanger, Inc.
14.3.1.1. Company Overview
14.3.1.2. Product Portfolio
14.3.1.3. SWOT Analysis
14.3.1.4. Financial Overview
14.3.1.5. Strategic Overview
14.3.2. Bayer Group (Dr. Scholl’s)
14.3.2.1. Company Overview
14.3.2.2. Product Portfolio
14.3.2.3. SWOT Analysis
14.3.2.4. Financial Overview
14.3.2.5. Strategic Overview
14.3.3. A. Algeo Limited
14.3.3.1. Company Overview
14.3.3.2. Product Portfolio
14.3.3.3. SWOT Analysis
14.3.3.4. Financial Overview
14.3.3.5. Strategic Overview
14.3.4. Bauerfeind AG
14.3.4.1. Company Overview
14.3.4.2. Product Portfolio
14.3.4.3. SWOT Analysis
14.3.4.4. Financial Overview
14.3.4.5. Strategic Overview
14.3.5. Superfeet Worldwide, Inc.
14.3.5.1. Company Overview
14.3.5.2. Product Portfolio
14.3.5.3. SWOT Analysis
14.3.5.4. Financial Overview
14.3.5.5. Strategic Overview
14.3.6. Ottobock SE & Co. KGaA (Ottobock Holding)
14.3.6.1. Company Overview
14.3.6.2. Product Portfolio
14.3.6.3. SWOT Analysis
14.3.6.4. Financial Overview
14.3.6.5. Strategic Overview
14.3.7. Pfizer, Inc.
14.3.7.1. Company Overview
14.3.7.2. Product Portfolio
14.3.7.3. SWOT Analysis
14.3.7.4. Financial Overview
14.3.7.5. Strategic Overview
14.3.8. Sanofi
14.3.8.1. Company Overview
14.3.8.2. Product Portfolio
14.3.8.3. SWOT Analysis
14.3.8.4. Financial Overview
14.3.8.5. Strategic Overview
14.3.9. GlaxoSmithKline plc
14.3.9.1. Company Overview
14.3.9.2. Product Portfolio
14.3.9.3. SWOT Analysis
14.3.9.4. Financial Overview
14.3.9.5. Strategic Overview